Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
14,57 AUD | -2,80% | +1,32% | -8,94% |
14/03 | Clinuvel Pharmaceuticals lanceert aandeleninkoopprogramma | MT |
14/03 | CLINUVEL PHARMACEUTICALS LIMITED : Morgans Financial past advies aan | ZM |
Vakgebied
Verkoop per activiteit
AUD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100,0
%
| 66 | 100,0 % | 78 | 100,0 % | +19,17% |
Verkoop per regio
AUD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Europe & United States
92,3
%
| 60 | 91,5 % | 72 | 92,3 % | +20,19% |
Switzerland, Others
7,7
%
| 6 | 8,5 % | 6 | 7,7 % | +8,19% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 01-11-05 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 01-11-05 |
Lachlan Hay
COO | Chief Operating Officer | - | 01-01-07 |
Dennis J. Wright
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 01-11-05 |
Director/Board Member | - | 06-02-07 | |
Karen Agersborg
BRD | Director/Board Member | - | 29-01-18 |
Susan Smith
BRD | Director/Board Member | - | 23-09-19 |
Chairman | - | 26-11-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 50 127 270 | 39 883 495 ( 79,56 %) | 0 | 79,56 % |
Bedrijfsgegevens
Clinuvel Pharmaceuticals Ltd.
535 Bourke Street Level 11
3000, Melbourne
+61 3 9660 4900
http://www.clinuvel.comSector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-8,94% | 489 mln. | |
-4,66% | 87,53 mld. | |
+2,63% | 40,42 mld. | |
-21,76% | 29,48 mld. | |
+55,89% | 25,43 mld. | |
-14,78% | 15,59 mld. | |
-18,49% | 11,49 mld. | |
-15,61% | 11,1 mld. | |
-44,02% | 11,3 mld. | |
+4,19% | 8,75 mld. |